C
Catamaran Bio
Innovative CAR NK cell therapies leveraging synthetic biology and non-viral engineering to treat diverse cancer types
About Catamaran Bio
Catamaran Bio is a pioneering biotechnology startup focused on developing advanced cell therapies to treat cancer. The company specializes in harnessing the natural cancer-fighting properties of NK (Natural Killer) cells, which are a type of immune cell that can target and destroy cancer cells. By leveraging synthetic biology and innovative non-viral cell engineering techniques, Catamaran Bio creates novel CAR (Chimeric Antigen Receptor) NK cell therapies. These therapies are designed to treat a broader range of cancer patients, particularly those with solid tumors, which are often more challenging to treat than blood cancers.
Catamaran Bio operates within the biotechnology and healthcare markets, specifically targeting the oncology sector. Its primary clients include healthcare providers, research institutions, and pharmaceutical companies that are involved in cancer treatment and research. The company's business model revolves around the development and commercialization of its proprietary cell therapy products. It generates revenue through partnerships, licensing agreements, and potentially through the direct sale of its therapies once they receive regulatory approval.
The core of Catamaran Bio's innovation lies in its TAILWIND platform, a proprietary suite of technologies designed to engineer, expand, and process NK cells into safe and highly effective allogeneic (donor-derived) CAR NK cell therapy products. This platform enables the company to produce therapies that are not only potent but also scalable, making them accessible to a larger patient population.
Recent developments highlight Catamaran Bio's progress and strategic collaborations. For instance, the company has presented promising preclinical data at major cancer research conferences and has partnered with OmniaBio for the development and manufacturing of its therapies. Additionally, a strategic platform license agreement with MaxCyte supports its CAR NK cell therapy programs, underscoring the company's commitment to advancing its innovative treatments.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2020 | $38M | $55M | Sofinnova Partners · SV Health Investors · Takeda Ventures · Lightstone Ventures | — |
| SPINOUT✓Other financing | Feb 2020 | $0 | — | University of Minnesota Twin Cities | — |
Growth signals
Latest recorded traffic for Catamaran Bio is 1.7K monthly website visits, up 21.4% over the last three months. Catamaran Bio's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Lightstone Ventures
Sofinnova Partners
SV Health Investors
Takeda Ventures
Astellas Venture
Other known investors2 additional known investors
University of Minnesota Twin Cities
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Catamaran Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Catamaran Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.